- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of August 5
The Center for Biosimilars® recaps the top stories for the week of August 5, 2019.
Transcript
Hi, I’m Jaime Rosenberg for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of August 5, 2019.
Number 5: Concerns are rising that the marketplace may soon see the advent of authorized biologics, which are similar to authorized generics.
Number 4: Cancer Care Ontario is launching new educational materials as Canada awaits the arrival of additional anticancer biosimilars.
Number 3: A retrospective analysis of care delivery at Memorial Sloan Kettering Cancer Center showed that using subcutaneous rituximab resulted in substantial time savings.
Number 2: A new systematic review reported on real-world evidence on biosimilar etanercept in the treatment of inflammatory diseases.
Number 1: Momenta says that it is stopping work on its proposed adalimumab biosimilar after changes in the market related to Humira patent settlements.
Finally, last week, our e-newsletter asked whether you think that, if given the opportunity, Congress should make some changes to the existing Biologics Price Competition and Innovation Act.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
